CohBar Past Earnings Performance
Past criteria checks 0/6
CohBar has been growing earnings at an average annual rate of 2.5%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
2.5%
Earnings growth rate
18.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -133.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
CohBar stock gains on 1-for-30 reverse stock split
Sep 22Here's Why We're Watching CohBar's (NASDAQ:CWBR) Cash Burn Situation
Jun 13
CohBar appoints Joseph Sarret as CEO and Director
Apr 27CohBar collaborates with NIAID for CB5064 analogs in COVID-19-related ARDS
Jan 11CohBar EPS in-line
Nov 16CohBar (CWBR) Investor Presentation - Slideshow
Oct 31Revenue & Expenses BreakdownBeta
How CohBar makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -13 | 9 | 4 |
| 31 Mar 23 | 0 | -11 | 6 | 5 |
| 31 Dec 22 | 0 | -12 | 6 | 6 |
| 30 Sep 22 | 0 | -11 | 7 | 5 |
| 30 Jun 22 | 0 | -12 | 7 | 5 |
| 31 Mar 22 | 0 | -15 | 8 | 7 |
| 31 Dec 21 | 0 | -15 | 8 | 8 |
| 30 Sep 21 | 0 | -17 | 7 | 10 |
| 30 Jun 21 | 0 | -17 | 7 | 9 |
| 31 Mar 21 | 0 | -16 | 6 | 8 |
| 31 Dec 20 | 0 | -16 | 6 | 7 |
| 30 Sep 20 | 0 | -15 | 6 | 6 |
| 30 Jun 20 | 0 | -15 | 6 | 7 |
| 31 Mar 20 | 0 | -14 | 6 | 7 |
| 31 Dec 19 | 0 | -13 | 6 | 7 |
| 30 Sep 19 | 0 | -14 | 6 | 7 |
| 30 Jun 19 | 0 | -15 | 6 | 8 |
| 31 Mar 19 | 0 | -15 | 6 | 9 |
| 31 Dec 18 | 0 | -16 | 5 | 10 |
| 30 Sep 18 | 0 | -14 | 4 | 10 |
| 30 Jun 18 | 0 | -13 | 4 | 9 |
| 31 Mar 18 | 0 | -11 | 3 | 8 |
| 31 Dec 17 | 0 | -10 | 3 | 7 |
| 30 Sep 17 | 0 | -9 | 3 | 6 |
| 30 Jun 17 | 0 | -7 | 3 | 5 |
| 31 Mar 17 | 0 | -7 | 3 | 4 |
| 31 Dec 16 | 0 | -6 | 2 | 4 |
| 30 Sep 16 | 0 | -6 | 2 | 3 |
| 30 Jun 16 | 0 | -5 | 2 | 3 |
| 31 Mar 16 | 0 | -4 | 2 | 2 |
| 31 Dec 15 | 0 | -4 | 2 | 2 |
| 30 Sep 15 | 0 | -3 | 2 | 1 |
| 30 Jun 15 | 0 | -3 | 1 | 1 |
| 31 Mar 15 | 0 | -2 | 2 | 1 |
| 31 Dec 14 | 0 | -2 | 1 | 1 |
| 30 Sep 14 | 0 | -2 | 1 | 0 |
| 30 Jun 14 | 0 | -1 | 1 | 0 |
| 31 Mar 14 | 0 | -1 | 0 | 0 |
Quality Earnings: CWBR is currently unprofitable.
Growing Profit Margin: CWBR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CWBR is unprofitable, but has reduced losses over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare CWBR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CWBR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CWBR has a negative Return on Equity (-133.49%), as it is currently unprofitable.